このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

BioSig Technologies マネジメント

マネジメント基準チェック /04

現在、CEO に関する十分な情報がありません。

主要情報

Anthony Amato

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	less than a year
CEOの所有権	n/a
経営陣の平均在職期間	less than a year
取締役会の平均在任期間	1.3yrs

経営陣の近況

Shareholders May Be More Conservative With BioSig Technologies, Inc.'s (NASDAQ:BSGM) CEO Compensation For Now

Dec 12

Recent updates

Shareholders May Be More Conservative With BioSig Technologies, Inc.'s (NASDAQ:BSGM) CEO Compensation For Now

Dec 12

Shareholders May Not Be So Generous With BioSig Technologies, Inc.'s (NASDAQ:BSGM) CEO Compensation And Here's Why

Dec 14

CEO（最高経営責任者

Anthony Amato (56 yo)

less than a year

在職期間

Mr. Anthony Amato served as Member of Advisory Board at BioSig Technologies, Inc. since 2021 and serves as its CEO & Director since April 30, 2024. He has corporate expertise in the medical industry. He fo...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Frederick Hrkac	President	less than a year	US$701.58k	3.59% $ 176.3k
Anthony Amato	CEO & Director	less than a year	データなし	データなし
Ferdinand Groenewald	Interim CFO & Principal Accounting Officer	no data	データなし	データなし
Budimir Drakulic	Chief Scientist	15.3yrs	US$628.04k	データなし

0.3yrs

平均在職期間

57yo

平均年齢

経験豊富な経営陣: BSGMの経営陣は経験豊富とはみなされません ( 0.3年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Frederick Hrkac	President	less than a year	US$701.58k	3.59% $ 176.3k
Anthony Amato	CEO & Director	less than a year	データなし	データなし
Zachariah Zachariah	Member of Advisory Board	4.3yrs	データなし	データなし
Lorraine Spurge	Member of Advisory Board	1.3yrs	データなし	データなし
Edwin Wang	Member of Advisory Board	1.3yrs	データなし	データなし
Sim Farar	Member of Advisory Board	6.1yrs	データなし	データなし
Ramachandra Malya	Member of Advisory Board	6.3yrs	データなし	データなし
Frank Quintero	Member of Advisory Board	5.2yrs	データなし	データなし
Chris Baer	Independent Director	less than a year	データなし	データなし
Steven Abelman	Independent Director	less than a year	データなし	データなし
Donald Browne	Independent Director	less than a year	データなし	データなし

1.3yrs

平均在職期間

58yo

平均年齢

経験豊富なボード: BSGMの取締役会は経験豊富ではない ( 1.3年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

BioSig Technologies マネジメント

マネジメント 基準チェック /04

主要情報

経営陣の近況

BioSig Technologies, Inc. Appoints Anthony Amato as Chief Executive Officer

Biosig Technologies, Inc. Announces Resignation of Kenneth L. Londoner as Chief Executive Officer

Shareholders May Be More Conservative With BioSig Technologies, Inc.'s (NASDAQ:BSGM) CEO Compensation For Now

Biosig Technologies, Inc. Appoints Fred Hrkac as Executive Vice President

BioSig Technologies, Inc., Annual General Meeting, Dec 18, 2023

BioSig Technologies, Inc. Announces Chief Financial Officer Changes

Recent updates

Nasdaq Hearings Panel Determines to Delist BioSig Technologies' Common Stock

BioSig Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $3.000005 million.

BioSig Technologies, Inc. announced delayed 10-Q filing

BioSig Technologies Regains Compliance with the Minimum Bid Price Requirements in Listing Rule 5550(a)(2)

BioSig Technologies, Inc. Appoints Anthony Amato as Chief Executive Officer

BioSig Technologies, Inc. announced delayed annual 10-K filing

BioSig Technologies Receives Letter from Nasdaq Regarding No Longer Meets the Requirement of Rule 5550(b)(2)

BioSig Technologies Receives a Letter from the Listing Qualifications Department of Nasdaq Stating That the Company Has Not Regained Compliance with the Rule

Biosig Technologies, Inc. Announces Resignation of Kenneth L. Londoner as Chief Executive Officer

BioSig Announces Reduction of its Workforce

Biosig Technologies, Inc. Commences Workforce Reduction Consisted of the Departure of Sixteen Employees

BioSig Technologies, Inc. announced that it expects to receive $1.04 million in funding

BioSig Technologies Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Market Value of Listed Securities

Consensus revenue estimates decrease by 67%, EPS upgraded

Shareholders May Be More Conservative With BioSig Technologies, Inc.'s (NASDAQ:BSGM) CEO Compensation For Now

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

BioSig Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $2.5 million.

BioSig Technologies, Inc. has filed a Follow-on Equity Offering.

BioSig Technologies, Inc. has filed a Follow-on Equity Offering.

Biosig Technologies, Inc. Appoints Fred Hrkac as Executive Vice President

BioSig Technologies, Inc., Annual General Meeting, Dec 18, 2023

BioSig Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $0.13464 million.

BioSig Technologies, Inc. announced that it has received $0.597497 million in funding

Price target increased by 27% to US$5.63

Consensus revenue estimates decrease by 24%

BioSig Technologies, Inc. announced that it has received $0.549999 million in funding

BioSig Technologies, Inc. Achieves Infrastructure and Technology Progress in Development of Generative AI Platform for Hospitals

Biosig Technologies, Inc. Introduces New Subscription Model for Pure Ep™ Platform, Offering Quicker Access to Latest Features, Customers

Biosig Technologies, Inc.'s Pure Ep Platform Debuts New Automated Features in First Patient Cases

Second quarter 2023 earnings released: US$0.16 loss per share (vs US$0.15 loss in 2Q 2022)

New minor risk - Share price stability

BioSig Technologies, Inc. Advances Collaboration on Machine Learning and Artificial Intelligence Solutions for Healthcare

Price target increased by 8.0% to US$4.50

Consensus EPS estimates fall by 24%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates decrease by 65%, EPS upgraded

BioSig Technologies, Inc. Announces Chief Financial Officer Changes

BioSig Technologies, Inc. announced that it has received $1.299999 million in funding

BioSig Technologies, Inc. announced that it expects to receive $0.159998 million in funding

BioSig Technologies, Inc. announced that it expects to receive $1.299999 million in funding

BioSig's PURE EP(TM) System Demonstrates Potential Time and Cost Savings At the 15th APHRS Scientific Session in Singapore

Shareholders May Not Be So Generous With BioSig Technologies, Inc.'s (NASDAQ:BSGM) CEO Compensation And Here's Why

BioSig Technologies Receives a Letter from the Nasdaq Stock Market

Consensus forecasts updated

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$4.17

BioSig Technologies, Inc., Annual General Meeting, Dec 20, 2022

BioSig Technologies Receives Letter from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid Price

BioSig in acquisition pact with San Antonio Hospital for cardiac signal system

BioSig Technologies, Inc. Launches PURE EP™ Software Version 6 with ACCUVIZ™ Module

BioSig: No Changes To Hold Thesis Following Q2 Earnings

Consensus forecasts updated

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

BioSig Technologies Receives Non-Compliance Letter from Nasdaq

Consensus revenue estimates fall by 55%

BioSig signs purchase deal with Kansas City's Overland Park Regional hospital

BioSig: PURE EP Economics Trade Exhausted

BioSig Technologies, Inc.’s PURE EP™ System to be Featured During EPLive 2022

Consensus revenue estimates fall by 18%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$8.50

Consensus forecasts updated

No longer forecast to breakeven

CEO（最高経営責任者

在職期間

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

マネジメント基準チェック /04